75 related articles for article (PubMed ID: 38504374)
1. TAZ is involved in breast cancer cell migration via regulating actin dynamics.
Choi HS; Jang HJ; Kristensen MK; Kwon TH
Front Oncol; 2024; 14():1376831. PubMed ID: 38774409
[TBL] [Abstract][Full Text] [Related]
2. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract][Full Text] [Related]
3. ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK.
Cui L; Lu Y; Zheng J; Guo B; Zhao X
J Exp Clin Cancer Res; 2023 Dec; 42(1):335. PubMed ID: 38057867
[TBL] [Abstract][Full Text] [Related]
4. MYH9 is a novel cancer stem cell marker and prognostic indicator in esophageal cancer that promotes oncogenesis through the PI3K/AKT/mTOR axis.
Kai JD; Cheng LH; Li BF; Kang K; Xiong F; Fu JC; Wang S
Cell Biol Int; 2022 Dec; 46(12):2085-2094. PubMed ID: 36030536
[TBL] [Abstract][Full Text] [Related]
5. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
6. Circ_0000511 accelerates the proliferation, migration and invasion, and restrains the apoptosis of breast cancer cells through the miR‑326/TAZ axis.
Wu D; Jia H; Zhang Z; Li S
Int J Oncol; 2021 Apr; 58(4):. PubMed ID: 33649821
[TBL] [Abstract][Full Text] [Related]
7. Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway.
Liu Y; Jiang Q; Liu X; Lin X; Tang Z; Liu C; Zhou J; Zhao M; Li X; Cheng Z; Li L; Xie Y; Liu Z; Fang W
EBioMedicine; 2019 Oct; 48():386-404. PubMed ID: 31594754
[TBL] [Abstract][Full Text] [Related]
8. TMEM120A-mediated regulation of chemotherapy sensitivity in colorectal cancer cells.
Wang L; Liu X
Cancer Chemother Pharmacol; 2024 Jan; 93(1):11-22. PubMed ID: 37728615
[TBL] [Abstract][Full Text] [Related]
9. Control of stem cell renewal and fate by YAP and TAZ.
Driskill JH; Pan D
Nat Rev Mol Cell Biol; 2023 Dec; 24(12):895-911. PubMed ID: 37626124
[TBL] [Abstract][Full Text] [Related]
10. Insights into recent findings and clinical application of YAP and TAZ in cancer.
Franklin JM; Wu Z; Guan KL
Nat Rev Cancer; 2023 Aug; 23(8):512-525. PubMed ID: 37308716
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells.
Sun Y; Hu L; Tao Z; Jarugumilli GK; Erb H; Singh A; Li Q; Cotton JL; Greninger P; Egan RK; Tony Ip Y; Benes CH; Che J; Mao J; Wu X
Nat Commun; 2022 Nov; 13(1):6744. PubMed ID: 36347861
[TBL] [Abstract][Full Text] [Related]
12. BAIAP2L1 accelerates breast cancer progression and chemoresistance by activating AKT signaling through binding with ribosomal protein L3.
Deng N; Zhang X; Zhang Y
Cancer Sci; 2023 Mar; 114(3):764-780. PubMed ID: 36308067
[TBL] [Abstract][Full Text] [Related]
13. P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer.
Li J; Zhang X; Hou Z; Cai S; Guo Y; Sun L; Li A; Li Q; Wang E; Miao Y
Cell Death Dis; 2022 Sep; 13(9):783. PubMed ID: 36088346
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
